The pharmaceutical company said Thursday that it will pay up to 48 million pounds ($62.60 million) to Adaptimmune (ADAP) for obtaining a license for investigational SPEAR T-cell receptor therapy for treating NY-ESO-1, a type of cancer tumor. Glaxo will ...and more »
Friday, 8 September 2017
Glaxo Exercises License Option for Investigational Cancer Treatment
The pharmaceutical company said Thursday that it will pay up to 48 million pounds ($62.60 million) to Adaptimmune (ADAP) for obtaining a license for investigational SPEAR T-cell receptor therapy for treating NY-ESO-1, a type of cancer tumor. Glaxo will ...and more »
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment